title: Iron chelators: mode of action as antimalarials.
abstract: Malaria parasites growing inside human erythrocytes differ from mammalian cells in their mode of acquisition of bioavailable iron and in their susceptibility to the antiproliferative action of iron chelators. We have assessed here three major properties associated with these phenomena: (a) the stage-dependent nature of parasite iron mobilization from the host and its integration into parasite proteins; (b) the differential permeability of the plasma membrane to iron chelators, and (c) the in situ generation of toxic chelator-metal complexes in the intracellular milieu of infected cells. We have used a combination of synthetic and natural iron chelators with similar iron-binding properties but markedly different capacities to permeate membranes. The profiles of action of these agents on the in vitro growth of Plasmodium falciparum were assessed in terms of inhibitory concentrations, speed of action, stage dependence and reversibility of effects. These profiles provided the basis for a working model of chelator action on parasitized cells. The model allowed us to predict major improvements in the antimalarial performance of iron chelators when used in appropriate combinations of slow-and fast-permeating substances. The synergistic actions found in vitro for various combinations of iron chelators are in accordance with the model and have implications for the design of therapeutic schemes.
authors.affiliation: Department of Biological Chemistry, Institute of Life Sciences, Hebrew University, Jerusalem, Israel.
authors.forename: Z I
authors.initials: ZI
authors.lastname: Cabantchik
authors.forename: H
authors.initials: H
authors.lastname: Glickstein
authors.forename: J
authors.initials: J
authors.lastname: Golenser
authors.forename: M
authors.initials: M
authors.lastname: Loyevsky
authors.forename: A
authors.initials: A
authors.lastname: Tsafack
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000378:metabolism / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D004912:Erythrocytes / Q000469:parasitology; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000378:metabolism / Q000494:pharmacology*; D010961:Plasmodium / Q000187:drug effects* / Q000254:growth & development; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000962:Antimalarials; D007502:Iron Chelating Agents; D007501:Iron